Jardiance Insurance Denial Appeal Guide

Why Jardiance Gets Denied

SGLT2 inhibitors are a competitive drug class. Each insurer has a preferred agent — if your plan prefers Farxiga over Jardiance (or vice versa), your claim may be denied even though the drugs are similar.

Common Denial Reasons

• Non-preferred SGLT2 inhibitor (plan prefers Farxiga or Invokana)
• Prior authorization missing
• A1c not high enough (some plans require A1c >7% or >8%)
• Step therapy not met (must try metformin first)
• Heart failure or CKD indication not on approved list

How to Appeal

1. Document why Jardiance specifically — EMPA-REG OUTCOME trial showed 38% reduction in cardiovascular death
2. If preferred alternative failed — document side effects or inadequate response
3. For heart failure indication — cite EMPEROR-Reduced and EMPEROR-Preserved trials
4. For CKD — cite EMPA-KIDNEY trial showing kidney protection
5. Get cardiologist or nephrologist support if using for non-diabetes indications

Strong Appeal Points

Jardiance has the strongest cardiovascular mortality data of any SGLT2 inhibitor. If your patient has established cardiovascular disease, this is a powerful argument for Jardiance specifically over other agents in the class.